96 related articles for article (PubMed ID: 182348)
1. Response of plasma fibrinogen and plasminogen to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer.
Seal US; Doe RP; Byar DP; Corle DK
Cancer; 1976 Sep; 38(3):1108-17. PubMed ID: 182348
[TBL] [Abstract][Full Text] [Related]
2. Response of serum cholesterol and triglycerides to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer.
Seal US; Doe RP; Byar DP; Corle DK
Cancer; 1976 Sep; 38(3):1095-107. PubMed ID: 182347
[TBL] [Abstract][Full Text] [Related]
3. Response of serum haptoglobin to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer.
Seal US; Doe RP; Byar DP; Corle DK
Cancer; 1978 Oct; 42(4):1720-9. PubMed ID: 213184
[No Abstract] [Full Text] [Related]
4. Correlation of pretreatment serum nonprotein-bound cortisol and total 17-hydroxycorticosteroid values with survival in patients with prostatic cancer.
Blackard CE; Byar DP; Seal US; Doe RP
N Engl J Med; 1974 Oct; 291(15):751-5. PubMed ID: 4369891
[No Abstract] [Full Text] [Related]
5. The effects of diethylstilbestrol and medroxyprogesterone acetate on kinetics and production of testosterone and dihydrotestosterone in patients with prostatic carcinoma.
Nolten WE; Sholiton LJ; Srivastava LS; Knowles HC; Werk EE
J Clin Endocrinol Metab; 1976 Dec; 43(6):1226-33. PubMed ID: 1002814
[TBL] [Abstract][Full Text] [Related]
6. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen.
Gallagher JC; Kable WT; Goldgar D
Am J Med; 1991 Feb; 90(2):171-8. PubMed ID: 1847582
[TBL] [Abstract][Full Text] [Related]
7. Treatment of breast cancer with medroxyprogesterone acetate.
Muggia FM; Cassieth PA; Ochoa M; Flatow FA; Gellhorn A; Hyman GA
Ann Intern Med; 1968 Feb; 68(2):328-37. PubMed ID: 4306126
[TBL] [Abstract][Full Text] [Related]
8. A critical analysis of tumor morphology and hormone treatments in the untreated and estrogen-treated responsive and refractory human prostatic carcinoma.
Sinha AA; Blackard CE; Seal US
Cancer; 1977 Dec; 40(6):2836-50. PubMed ID: 201356
[No Abstract] [Full Text] [Related]
9. [Behavior of plasminogen in prostatic carcinoma treated with cytonal].
Oehler D; Kätzel R; Brunner HP
Z Urol Nephrol; 1980 Dec; 73(12):923-9. PubMed ID: 6452764
[TBL] [Abstract][Full Text] [Related]
10. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies.
Byar DP; Corle DK
NCI Monogr; 1988; (7):165-70. PubMed ID: 3050535
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of prostatic cancer: medroxyprogesterone acetate, diethylstilbestrol and cyproterone acetate. Provisional report of a random study by the genito-urinary cooperative group of the EORTC].
Pavone-Macaluso M; Martínez-Piñeiro JA; de Voogt H; Lardennois B; Nasta A; Zolfanelli R; Barasolo E; De Pauw M; Suciu S; Sulvester R
Arch Esp Urol; 1982; 35(5):304-11. PubMed ID: 6217788
[No Abstract] [Full Text] [Related]
12. Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761.
Pavone-Macaluso M; Ingargiola GB; de Voogt H; Viggiano G; Barasolo E; Lardennois B; De Pauw M; Sylvester R
Prog Clin Biol Res; 1987; 243A():379-82. PubMed ID: 2958862
[No Abstract] [Full Text] [Related]
13. Cancer of the prostate:estrogen therapy: natural conjugated estrogen vs. Stillbestrol: A point of view.
Kaplan L
Rev Surg; 1968; 25(5):323-9. PubMed ID: 4301296
[No Abstract] [Full Text] [Related]
14. Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer.
Shearer RJ; Hendry WF; Sommerville IF; Fergusson JD
Br J Urol; 1973 Dec; 45(6):668-77. PubMed ID: 4359746
[No Abstract] [Full Text] [Related]
15. The effect of estrogen-progestin treatment on opioid control of gonadotropin and prolactin secretion in postmenopausal women.
Dawood MY; Khan-Dawood FS; Ramos J
Am J Obstet Gynecol; 1986 Dec; 155(6):1246-51. PubMed ID: 3024488
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.
Pomerantz M; Manola J; Taplin ME; Bubley G; Inman M; Lowell J; Beard C; Kantoff PW; Oh WK
J Urol; 2007 Jun; 177(6):2146-50. PubMed ID: 17509304
[TBL] [Abstract][Full Text] [Related]
17. EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
Pavone-Macaluso M; Schröder FH; de Voogt HJ; Viggiano G; Barasolo E; Lardennois B; de Pauw M; Sylvester R; Smith PH; Suciu S
Prog Clin Biol Res; 1989; 303():111-6. PubMed ID: 2528735
[No Abstract] [Full Text] [Related]
18. [Plasma changes caused by estrogens in the vascular risk of prostatic carcinoma over a 3-year period].
Daponte DP; Stevens I; Robinson MR
Actas Urol Esp; 1986; 10(6):437-40. PubMed ID: 3825644
[No Abstract] [Full Text] [Related]
19. The EORTC Phase III trials in prostatic cancer.
Robinson MR; Smith PH; Macaluso MP; Sylvester R; de Voogt H
Prog Clin Biol Res; 1985; 185A():243-9. PubMed ID: 3898132
[No Abstract] [Full Text] [Related]
20. Hormone therapy in prostatic cancer.
Smith PH; Akdas A; Mason MK; Richards B; Robinson MR; de Pauw M; Sylvester R
Acta Urol Belg; 1980 Jan; 48(1):98-105. PubMed ID: 7001876
[No Abstract] [Full Text] [Related]
[Next] [New Search]
